bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2020-65-3-335-350bloodjour-236Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREРоль интерлейкина-3 и его рецептора в патогенезе острых лейкозовThe role of interleukin-3 and its receptor in acute leukemia pathogenesishttps://orcid.org/0000-0001-8973-9407БальжановаЯ. Б.BalzhanovaY. B.

Бальжанова Янжима Базаровна, врач-гематолог отделения интенсивной высокодозной химиотерапии гематологических заболеваний с  круглосуточным и дневным стационаром

Yanzhima B. Balzhanova, hematologist in the Department of Intensive Highdose Chemotherapy of Hematological Diseases With Round-the-clock and Day Hospitals

ybalzh11@gmail.comhttps://orcid.org/0000-0001-8188-5557СавченкоВ. Г.SavchenkoV. G.

Савченко Валерий Григорьевич, доктор медицинских наук, профессор, академик РАН, генеральный директор

Valeriy G. Savchenko, Dr. Sci. (Med.), Professor, Chief Hematology Specialist of the Ministry of Health of the Russian Federation, RAS Academician, Head

director@blood.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for HematologyRussian Federation202020092020653335350Copyright © Бальжанова Я.Б., Савченко В.Г., 20202020Бальжанова Я.Б., Савченко В.Г.Balzhanova Y.B., Savchenko V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/236Введение

Введение. Интерлейкин-3 (ИЛ-3) является важным цитокином, регулирующим процесс нормального кроветворения. Часто лейкемические клетки экспрессируют α-цепь рецептора ИЛ-3 (CD123).

Цель

Цель: обобщить современное представление о значении ИЛ-3 и его рецептора CD123 в патогенезе острых лейкозов.

Основные сведения

Основные сведения. ИЛ-3 регулирует пролиферацию и  дифференцировку нормальных кроветворных клетокпредшественниц на ранних этапах гемопоэза. Рецептор ИЛ-3 (CD123) экспрессируется на нормальных кроветворных клетках. Подтверждена высокая экспрессия СD123 на бластных клетках острого миелоидного лейкоза, В-острого лимфобластного лейкоза и в популяции лейкоз-инициирующих клеток с фенотипом CD34+ CD38– . ИЛ-3 препятствует апоптозу опухолевых клеток и способствует их автономному росту. В настоящий момент разрабатывают и исследуют различные терапевтические подходы блокирования ИЛ-3 опосредованного сигнала.

Introduction

Introduction. Interleukin-3 (IL-3) is the key cytokine involved in the regulation of normal haematopoiesis. Some leukemic cells demonstrate high expression of the α-subunit of the receptor for interleukin-3 (CD123).

Aim

Aim: to summarize the current understanding of IL-3 and its receptor CD123 in the pathogenesis of acute leukemia.

General findings

General findings: IL-3 regulates the proliferation and differentiation of normal hematopoietic progenitor cells in the early stages of hematopoiesis. The IL-3 receptor (CD123) is expressed on normal hematopoietic cells. High expression of CD123 was confirmed on blast cells of AML, B-ALL and on the leukemia-initiating CD34+ CD38– cells. IL-3 inhibits apoptosis and promotes the autonomous growth of blast cells. Currently, different approaches of blocking the IL-3 mediated signal are being investigated.

острый лейкозинтерлейкин-3CD123лечениеacute leukemiainterleukin-3CD123treatmentReferencesПаровичникова Е.Н., Савченко В.Г. Российские многоцентровые исследования по лечению острых лейкозов. Терапевтический архив. 2019; 91(7): 4–13.Parovichnikova E.N., Savchenko V.G. Russian multicenter clinical trials in acute leukemias. Terapevticheskiy arkhiv. 2019; 91(7): 4–13. DOI: 10.26442/004036 60.2019.07.000325. (In Russian).Паровичникова Е.Н., Лукьянова И.А., Троицкая В.В. и др. Результаты программной терапии острых миелоидных лейкозов в ФГБУ «НМИЦ гематологии» Минздрава России. Терапевтический архив. 2018; 90(7): 14–22.Parovichnikova E.N., Luk’yanova I.A., Troitskaya V.V. et al. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation. Terapevticheskiy arkhiv. 2018; 90(7): 14–22. DOI: 10.26442/terarkh201890714-22. (In Russian).Гребенюк Л.А., Обухова Т.Н., Паровичникова Е.Н. и др. Аномалии хромосом 5, 7, 11 и 17 в комплексном кариотипе при миелодиспластических синдромах и острых миелоидных лейкозах. Медицинская генетика. 2018; 17(6): 39–47.Grebenyuk L.A., Obukhova T.N., Parovichnikova E.N. et al. Anomalies of chr mosomes 5, 7, 11 and 17 with complex karyotype in myelodysplastic syndrome and acute myeloid leukemia patients. Meditsinskaya genetika. 2018; 17(6): 39– 47. DOI: 10.25557/2073-7998.2018.06.39-47. (In Russian).Döhner H., Estey E., Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424–47. DOI: 10.1182/blood-2016-08-733196.Döhner H., Estey E., Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424–7. DOI: 10.1182/blood-2016-08-733196.Пискунова И.С., Обухова Т.Н., Паровичникова Е.Н. и др. Структура и значение цитогенетических перестроек у взрослых больных Ph негативным острым лимфобластным лейкозом. Терапевтический архив. 2018; 90(7): 30–7.Piskunova I.S., Obukhova T.N., Parovichnikova E.N. et al. Structure and signifi cance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia. Terapevticheskiy arkhiv. 2018; 90(7): 30–7 DOI: 10.26442/terarkh201890730-37. (In Russian).Topp M.S., Gökbuget N., Stein A.S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16(1): 57–66. DOI: 10.1016/S1470-2045(14)71170-2.Topp M.S., Gökbuget N., Stein A.S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16(1): 57–66. DOI: 10.1016/S1470-2045(14)71170-2.Басхаева Г.А., Паровичникова Е.Н., Бидерман Б.В. и др. Роль мутаций гена IKZF1 при В-клеточном остром лимфобластном лейкозе у взрослых больных, получающих лечение по протоколам российского многоцентрового исследования. Гематология и трансфузиология. 2018; 63(1): 16–30. DOI: 10.25837/HAT.2018.80..1..002.Baskhaeva G.A., Parovichnikova E.N., Biderman B.V. et al. The role of lKZFl deletions in adult Ph-negative and Ph-positive B-cell acute lymphoblastic leukemia patients treated in Russian Acute Lymphoblastic Leukemia study. Gematologiya i transfuziologiya. 2018; 63(1): 16–30. DOI: 10.25837/HAT.2018.80..1..002. (In Russian).Копнин Б.П. Современные представления о механизмах злокачественного роста: сходства и различия солидных опухолей и лейкозов. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2012; 5(3): 165–85.Kopnin B.P. Modern concepts of the mechanisms of tumor growth: similarities and differences between solid tumors and leukemia. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika. 2012; 5(3): 165–85. (In Russian).Дризе Н.И., Чертков И.Л. Цитокины и ростовые факторы в кроветворной системе. Клиническая онкогематология. Под ред. Волковой М.А. 2-е изд., перераб. и доп. М.: Медицина, 2007; 81–8.Drize N.I., Chertkov I.L. Cytokines and growth factors in the hematopoietic system. Klinicheskaya onkogematologiya. Volkova M.A., ed: 2nd edition, updated. Moscow: Meditsina Publishers; 2007: 81–8. (In Russian).Симбирцев А.С. Цитокины — новая система регуляции защитных реакций организма. Цитокины и воспаление. 2002; 1(1): 9–16.Simbirtsev A. S. Cytokines as a new system, regulating body defense reactions. Tsitokiny i vospalenie. 2002; 1(1): 9–16. (In Russian).Van der Lely N., De Witte T., Wessels J. et al. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol. 1994; 68(5): 225–232. DOI: 10.1007/bf01737421.Van der Lely N., De Witte T., Wessels J. et al. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol. 1994; 68(5): 225–32. DOI: 10.1007/bf01737421.Feuring-Buske M., Gerhard B., Cashman J. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia. 2003; 17(4): 760–3. DOI: 10.1038/sj.leu.2402882.Feuring-Buske M., Gerhard B., Cashman J. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-defi cient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia. 2003; 17(4): 760–63. DOI: 10.1038/sj.leu.2402882.Hunter A. E., Rogers S.Y., Roberts I.A. et al. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood. 1993; 82(3): 899–903. DOI: 10.1182/blood.V82.3.899.bloodjournal823899.Hunter A. E., Rogers S.Y., Roberts I.A. et al. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood. 1993; 82(3): 899-903. DOI: 10.1182/blood.V82.3.899.bloodjournal823899.Witz F., Sadoun A., Perrin M.C. et al. A placebo-controlled study of recombinant human granulocyte–macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998; 91: 2722–30. DOI: 10.1182/blood.V91.8.2722.2722_2722_2730.Witz F., Sadoun A., Perrin M.C. et al. A placebo-controlled study of recombinant human granulocyte–macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998; 91: 2722–30. DOI: 10.1182/blood.V91.8.2722.2722_2722_2730.Rowe J.M., Neuberg D., Friedenberg W. et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004; 103: 479–85. DOI: 10.1182/blood-2003-05-1686.Rowe J.M., Neuberg D., Friedenberg W. et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004; 103: 479–85. DOI: 10.1182/blood-2003-05-1686.Xavier L., Cunha M., Gonçalves C. et al. Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy. Leuk lymphoma. 2003; 44(12): 2137–42. DOI: 10.1080/1042819031000111053.Xavier L., Cunha M., Gonçalves C. et al. Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy. Leuk lymphoma. 2003; 44(12): 2137–42. DOI: 10.1080/1042819031000111053.Delwel R., Salem M., Pellens C. et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood. 1988; 72(6): 1944–49.Delwel R., Salem M., Pellens C. et al. Growth regulation of human acute myeloid leukemia: effects of fi ve recombinant hematopoietic factors in a serum-free culture system. Blood. 1988; 72(6): 1944–49.Blalock W. L., Weinstein-Oppenheimer C., Chang F. et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 1999; 13(8): 1109–66. DOI: 10.1038/sj.leu.2401493.Blalock W. L., Weinstein-Oppenheimer C., Chang F. et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 1999; 13(8): 1109–66. DOI: 10.1038/sj.leu.2401493.Sung P. J., Sugita M., Koblish H. et al. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Adv. 2019; 3(7): 1061–72. DOI: 10.1182/bloodadvances.2018029850.Sung P. J., Sugita M., Koblish H. et al. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Adv. 2019; 3(7): 1061–72. DOI: 10.1182/bloodadvances.2018029850.Sato N., Caux C., Kitamura T. et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood. 1993; 82(3): 752–61. DOI: 10.1182/blood.V82.3.752.bloodjournal823752.Sato N., Caux C., Kitamura T. et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood. 1993; 82(3): 752–61. DOI: 10.1182/blood.V82.3.752.bloodjournal823752.Militi S., Riccioni R., Parolini I. et al. Expression of interleukin 3 and granulocyte– macrophage colony‐stimulating factor receptor common chain βc, βIT in normal haematopoiesis: lineage specificity and proliferation‐independent induction. Brit J Haematol. 2000; 111(2): 441–51. DOI: 10.1111/j.1365-2141.2000.02348.x.Militi S., Riccioni R., Parolini I. et al. Expression of interleukin 3 and granulocyte– macrophage colony‐stimulating factor receptor common chain βc, βIT in normal haematopoiesis: lineage specifi city and proliferation‐independent induction. Brit J Haematol. 2000; 111(2): 441–51. DOI: 10.1111/j.1365-2141.2000.02348.x.Jordan C.T., Upchurch D., Szilvassy S.J. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10): 1777–84. DOI: 10.1038/sj.leu.2401903.Jordan C.T., Upchurch D., Szilvassy S.J. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10): 1777–84. DOI: 10.1038/sj.leu.2401903.Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1986; 67(2): 257–267. DOI: 10.1182/ blood.V67.2.257.257.Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1986; 67(2): 257–67. DOI: 10.1182/ blood.V67.2.257.257.Wielenga J.J., Vellenga E., Groenewegen A. et al. Recombinant human interleukin-3 (rh IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia. 1996; 10: 43–47.Wielenga J.J., Vellenga E., Groenewegen A. et al. Recombinant human interleukin-3 (rh IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia. 1996; 10: 43–7.Nimer S.D., Pacquette L., Ireland P. et al. A phase II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol. 1994; 22(9): 875–80.Nimer S.D., Pacquette L., Ireland P. et al. A phase II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol. 1994; 22(9): 875–80.Hurwitz N., Probst A., Zufferey G. et al. Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk lymphoma. 1996; 20(3–4): 337–40. DOI: 10.3109/10428199609051628.Hurwitz N., Probst A., Zufferey G. et al. Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk lymphoma. 1996; 20(3- 4): 337–40. DOI: 10.3109/10428199609051628.Reddy E.P., Korapati A., Chaturvedi P., Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene. 2000; 19(21): 2532–47. DOI: 10.1038/sj.onc.1203594.Reddy E.P., Korapati A., Chaturvedi P., Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene. 2000; 19(21): 2532–47. DOI: 10.1038/sj.onc.1203594.Wang J.M., Lai M.Z., Yang-Yen H.F. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU. 1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol Cell Biol. 2003; 23(6): 1896–909. DOI: 10.1128/MCB.23.6.1896-1909.2003.Wang J.M., Lai M.Z., Yang-Yen H.F. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU. 1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol Cell Biol. 2003; 23(6): 1896–909. DOI: 10.1128/MCB.23.6.1896-1909.2003.Jin L., Lee E.M., Ramshaw H.S. et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5(1): 31–42. DOI: 10.1016/j.stem.2009.04.018.Jin L., Lee E.M., Ramshaw H.S. et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5(1): 31–42. DOI: 10.1016/j.stem.2009.04.018.Bras A.E., de Haas V., van Stigt A. et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry Part B: Clinical Cytometry. 2019; 96(2): 134–42. DOI: 10.1002/cyto.b.21745.Bras A.E., de Haas V., van Stigt A. et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry Part B: Clinical Cytometry. 2019; 96(2): 134–42. DOI: 10.1002/cyto.b.21745.Hassanein N.M., Alcancia F., Perkinson K.R. et al. Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors (“hematogones”) and B lymphoblastic leukemia blasts. Am J Clin Pathol. 2009; 132(4): 573–80. DOI: 10.1309/AJCPO4DS0GTLSOEI.Hassanein N.M., Alcancia F., Perkinson K.R. et al. Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors (“hematogones”) and B lymphoblastic leukemia blasts. Am J Clin Pathol. 2009; 132(4): 573–80. DOI: 10.1309/AJCPO4DS0GTLSOEI.Testa U., Riccioni R., Militi S. et al. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002; 100(8): 2980–88. DOI: 10.1182/ blood-2002-03-0852.Testa U., Riccioni R., Militi S. et al. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002; 100(8): 2980–8. DOI: 10.1182/ blood-2002-03-0852.Ehninger A., Kramer M., Röllig C. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014; 4(6): e218. DOI: 10.1038/bcj.2014.39.Ehninger A., Kramer M., Röllig C. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014; 4(6): e218. DOI: 10.1038/bcj.2014.39.Rollins-Raval M., Pillai R., Warita K. et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol. 2013; 21(3): 212–217. DOI: 10.1097/PAI.0b013e318261a342.Rollins-Raval M., Pillai R., Warita K. et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol. 2013; 21(3): 212–7. DOI: 10.1097/PAI.0b013e318261a342.Wittwer N. L., Brumatti G., Marchant C. et al. High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression. Blood Adv. 2017; 1(15): 1067–79. DOI: 10.1182/bloodadvances.2016002931.Wittwer N. L., Brumatti G., Marchant C. et al. High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression. Blood Adv. 2017; 1(15): 1067–79. DOI: 10.1182/bloodadvances.2016002931.Clarkson B., Ohkita T., Ota K., Fried J. Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. J Clin Invest. 1967; 46(4): 506–29. DOI: 10.1172/JCI105553Clarkson B., Ohkita T., Ota K., Fried J. Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injections of tritiated thymidine. J Clin Invest. 1967; 46(4): 506–29. DOI: 10.1172/JCI105553.Thomas D., Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017; 129(12): 1577–85. DOI: 10.1182/ blood-2016-10-696054.Thomas D., Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017; 129(12): 1577–85. DOI: 10.1182/ blood-2016-10-696054Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7): 730–7. DOI: 10.1038/nm0797-730.Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7): 730–7. DOI: 10.1038/nm0797-730.Al-Mawali A., Gillis D., Lewis I. Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016; 9(1): 61. DOI: 10.1186/s13045-016-0292-z.Al-Mawali A., Gillis D., Lewis I. Immunoprofi ling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016; 9(1): 61. DOI: 10.1186/s13045-016-0292-z.Vergez F., Green A.S., Tamburini J. et al. High levels of CD34+ CD38low/− CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011; 96(12): 1792–8. DOI: 10.3324/haematol.2011.047894.Vergez F., Green A.S., Tamburini J. et al. High levels of CD34+ CD38low/− CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011; 96(12): 1792–8. DOI: 10.3324/haematol.2011.047894.Angelova E., Audette C., Kovtun Y. et al. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019; 104(4): 749–55. DOI: 10.3324/haematol.2018.205252.Angelova E., Audette C., Kovtun Y. et al. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019; 104(4): 749–55. DOI: 10.3324/haematol.2018.205252.Chen Z. Sun Y., Xie W. et al. Is hyperdiploidy a favorable cytogenetics in adults with B‐lymphoblastic leukemia? Cancer medicine. 2019; 8(9): 4093- 4099. DOI: 10.1002/cam4.2255.Chen Z. Sun Y., Xie W. et al. Is hyperdiploidy a favorable cytogenetics in adults with B‐lymphoblastic leukemia? Cancer medicine. 2019; 8(9): 4093–99. DOI: 10.1002/cam4.2255.Du W., Li J., Liu W. et al. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy. Tumor Biol. 2016; 37(3): 3817–21. DOI: 10.1007/s13277-015-3272-y.Du W., Li J., Liu W. et al. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy. Tumor Biol. 2016; 37(3): 3817–21. DOI: 10.1007/s13277-015-3272-y.Pemmaraju N., Lane A.A., Sweet K.L. et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019; 380(17): 1628–37. DOI: 10.1056/NEJMoa1815105.Pemmaraju N., Lane A.A., Sweet K.L. et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019; 380(17): 1628–37. DOI: 10.1056/NEJMoa1815105.Xiao W., Goldberg A.D., Famulare C. et al. Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis. Blood. 2018; 132(Suppl. 1): 2789. DOI: 10.1182/ blood-2018-99-119081.Xiao W., Goldberg A.D., Famulare C. et al. Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis. Blood. 2018; 132(Suppl. 1): 2789. DOI: 10.1182/ blood-2018-99-119081.He S.Z., Busfield S., Ritchie D.S. et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma. 2015; 56(5): 1406–15. DOI: 10.3109/10428194.2014.956316.He S.Z., Busfi eld S., Ritchie D.S. et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma. 2015; 56(5): 1406–15. DOI: 10.3109/10428194.2014.956316.Busfield S.J., Biondo M., Wong M. et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014; 28(11): 2213–21. DOI: 10.1038/leu.2014.128.Busfi eld S.J., Biondo M., Wong M. et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014; 28(11): 2213–21. DOI: 10.1038/leu.2014.128.Kubasch A.S., Schulze F., Götze K.S. et al. Anti-CD123 targeted therapy with Talacotuzumab in advanced MDS and AML after failing hypomethylating agentsfinal results of the Samba trial. Blood. 2018; 132(Suppl. 1): 4045. DOI: 10.1182/ blood-2018-99-113112.Kubasch A.S., Schulze F., Götze K.S. et al. Anti-CD123 targeted therapy with Talacotuzumab in advanced MDS and AML after failing hypomethylating agentsfi nal results of the Samba trial. Blood. 2018; 132(Suppl. 1): 4045. DOI: 10.1182/ blood-2018-99-113112.Hills R.K., Castaigne S., Appelbaum F.R. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014; 15(9): 986–96. DOI: 10.1016/S1470-2045(14)70281-5.Hills R.K., Castaigne S., Appelbaum F.R. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014; 15(9): 986–96. DOI: 10.1016/S1470-2045(14)70281-5.Daver N.G., Erba H.P., Papadantonakis N. et al. A phase I first-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia and other CD123-positive hematologic malignancies. Blood. 2018; 132 (Suppl 1): 27. DOI: 10.1182/blood-2018-99-112955.Daver N.G., Erba H.P., Papadantonakis N. et al. A phase I fi rst-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia and other CD123-positive hematologic malignancies. Blood. 2018; 132 (Suppl 1): 27. DOI: 10.1182/blood-2018-99-112955.Frankel A.E., Woo J.H., Ahn C. et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014; 124(3): 385–92. DOI: 10.1182/blood-2014-04-566737Frankel A.E., Woo J.H., Ahn C. et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014; 124(3): 385–92. DOI: 10.1182/blood-2014-04-566737.Frankel A., Liu J.S., Rizzieri D., Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leu kemia and myelodysplasia. Leuk Lymphoma. 2008; 49(3): 543–53. DOI: 10.1080/10428190701799035.Frankel A., Liu J.S., Rizzieri D., Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leu kemia and myelodysplasia. Leuk Lymphoma. 2008; 49(3): 543–53. DOI: 10.1080/10428190701799035.Stephansky J., Togami K., Ghandi M. et al. Resistance to SL-401 in AML and BPDCN is associated with loss of the diphthamide synthesis pathway enzyme DPH1 and is reversible by azacitidine. Blood. 2017; 130(Suppl. 1): 797. DOI: 10.1182/blood.V130.Suppl_1.797.797Stephansky J., Togami K., Ghandi M. et al. Resistance to SL-401 in AML and BPDCN is associated with loss of the diphthamide synthesis pathway enzyme DPH1 and is reversible by azacitidine. Blood. 2017; 130(Suppl. 1): 797. DOI: 10.1182/blood.V130.Suppl_1.797.797.https://clinicaltrials.gov/.https://clinicaltrials.gov/.Uy G.L., Rettig M.P., Vey N. et al. Phase 1 cohort expansion of fl otetuzumab, a CD123× CD3 bispecific DART® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood. 2018; 132(Suppl. 1): 764. DOI: 10.1182/ blood-2018-99-117085.Uy G.L., Rettig M.P., Vey N. et al. Phase 1 cohort expansion of fl otetuzumab, a CD123× CD3 bispecifi c DART® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood. 2018; 132(Suppl. 1): 764. DOI: 10.1182/ blood-2018-99-117085.Kügler M., Stein C., Kellner C. et al. A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol. 2010; 150(5): 574–86. DOI: 10.1111/j.1365-2141.2010.08300.x.Kügler M., Stein C., Kellner C. et al. A recombinant trispecifi c single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol. 2010; 150(5): 574–86. DOI: 10.1111/j.1365-2141.2010.08300.x.Бондаренко С.Н., Паровичникова Е.Н., Масчан А.А. и др. Блинатумомаб в терапии острого лимфобластного лейкоза: Российское многоцентровое исследование. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2019; 12(2): 45–53.Bondarenko S.N., Parovichnikova E.N., Maschan A.A. et al. Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial. Klinicheskaya onkogematologiya. Fundamental‘nye issledovaniya i klinicheskaya praktika. 2019; 12(2): 45–53. DOI: 10.21320/2500-2139-2019-12-2-145- 153. (In Russian).Ruella M., Barrett D.M., Kenderian S.S. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10): 3814–26. DOI: 10.1172/JCI87366.Ruella M., Barrett D.M., Kenderian S.S. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10): 3814–26 DOI: 10.1172/JCI87366.Глуханюк Е.В., Степанов А.В., Попов А.М., Масчан М.А. Механизмы резистентности В-линейного острого лимфобластного лейкоза при применении CD19-направленной иммунотерапии. Онкогематология. 2018; 13(4): 27–36.Glukhanyuk E.V., Stepanov A.V., Popov A.M., Maschan M.A. CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia. Onkogematologiya. 2018; 13(4): 27–36. DOI: 10.17650/1818-8346- 2018-13-4-27-36. (In Russian).Arcangeli S., Rotiroti M.C., Bardelli M. et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Therapy. 2017; 25(8): 1933–1945. DOI: 10.1016/j. ymthe.2017.04.017.Arcangeli S., Rotiroti M.C., Bardelli M. et al. Balance of anti-CD123 chimeric antigen receptor binding affi nity and density for the targeting of acute myeloid leukemia. Mol Therapy. 2017; 25(8): 1933–45. DOI: 10.1016/j.ymthe.2017.04.017

The authors declare that there are no conflicts of interest present.